AX-2025-020314
Semaglutide · 3 mg declared · Xi'an Mokemei Biotechnology Co., Ltd. · lot MKM-2507-D3230
- Report ID
- AX-2025-020314
- Compound
- Semaglutide
- Compound class
- Incretin analogues and co-agonists
- Supplier
- MKM — Xi'an Mokemei Biotechnology Co., Ltd.
- Batch / lot
- MKM-2507-D3230
- Declared label claim
- 3mg
- Laboratory
- Janoshik Analytical
- Assay date
- 04 Dec 2025
- Submitted
- 10 Dec 2025
- Quarter
- 2025-Q4
- Submitter
- n.bruun
- Sample provenance
- Supplier-supplied
Results
Measured against the index acceptance specification for the incretin analogues and co-agonists class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.
| Parameter | Method | Result | Unit | Index spec | |
|---|---|---|---|---|---|
| Purity | RP-HPLC, 30 min gradient, 214 nm | 99.00 | % area | ≥ 97.0 | PASS |
| Total impurities | RP-HPLC, sum of reported peaks | 1.00 | % area | ≤ 3.0 | PASS |
| Largest single impurity | RP-HPLC — [D-Aib8]-diastereomer | 0.41 | % area | ≤ 1.00 | PASS |
| Identity — theoretical monoisotopic mass | calculated from molecular formula | 4111.0524 | Da | — | NOT TESTED |
| Identity — observed monoisotopic mass | LC-MS, high resolution (ESI-TOF/QTOF) | 4111.0475 | Da | — | NOT TESTED |
| Mass accuracy | observed vs theoretical | -1.2 | ppm | ± 15 | PASS |
| Total peptide content | by difference from the gravimetric mass balance | 88.30 | %w/w | — | NOT TESTED |
| Target-compound content | total peptide content × purity | 87.42 | %w/w | — | NOT TESTED |
| Gross fill (as weighed) | five-place balance, under nitrogen | 3.19 | mg | 3 mg declared | NOT TESTED |
| Recovered target peptide | gross fill × target content | 2.789 | mg | 3 mg claim | NOT TESTED |
| Recovery against label claim | recovered ÷ claim | 93.0 | % | 90.0 – 110.0 | PASS |
| Water content | Karl Fischer, coulometric, duplicate | 4.63 | % | ≤ 8.0 | PASS |
| Counter-ion (TFA) | anion-exchange ion chromatography | 6.19 | % | ≤ 12.0 | PASS |
| Residual solvent + inorganic residue | estimated — see /methods/residual-solvents-q3c/ | 0.88 | % | — | NOT TESTED |
| Endotoxin | not ordered on this submission | not determined | — | ≤ 5.0 | NOT TESTED |
| Sterility | not ordered on this submission | not determined | — | no growth | NOT TESTED |
| Appearance | visual, diffuse light, black and white background | White lyophilised cake, intact | — | white to off-white intact cake | PASS |
| Reconstitution clarity | reconstituted per submitter procedure | Clear, colourless, no visible particulates | — | clear, no visible particulates | PASS |
| pH (reconstituted, 1 mg/mL) | potentiometric, two-point calibration | 3.19 | — | 2.5 – 8.0 | PASS |
| Retention time (observed) | RP-HPLC, 30 min gradient | 17.45 | min | 18.42 ± 0.45 (normalised) | FAIL |
| Peak asymmetry (10 % height) | Ph. Eur. 2.2.46 | 1.29 | — | 0.80 – 1.50 | PASS |
| Plate count, main peak | N = 5.54 (t/w½)² | 70,567 | — | ≥ 20,000 | PASS |
| Resolution to nearest impurity | vs [D-Aib8]-diastereomer | 0.89 | — | no index criterion | REPORTED |
Chromatogram and peak integration
The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.
| # | Peak | RT | Area (µV·s) | % area | Δ mass (Da) |
|---|---|---|---|---|---|
| 1 | Semaglutide — main peak | 17.45 | 4,811,707 | 99.00 | — |
| 2 | [D-Aib8]-diastereomer | 17.21 | 19,927 | 0.41 | 0.000 |
| 3 | C18 diacid mono-ester | 18.81 | 17,011 | 0.35 | +14.016 |
| 4 | des-AEEA semaglutide (−145 Da) | 16.63 | 8,263 | 0.17 | -145.074 |
| 5 | des-His1 truncate (−137 Da) | 16.31 | 1,944 | 0.04 | -137.059 |
| 6 | Met(O) sulfoxide (+16 Da) | 16.77 | 1,458 | 0.03 | +15.995 |
| Closure check — purity + Σ impurities | 100.00 | CLOSES | |||
Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.
Mass spectrum and identity
Theoretical monoisotopic mass 4111.0524 Da, computed from C187H291N45O59. All ppm figures on this site are against monoisotopic values — see why that matters.
| Charge | Theoretical m/z | Observed m/z | Δ m/z | Rel. abundance (%) |
|---|---|---|---|---|
| 6+ | 686.1827 | 686.1819 | -0.0008 | 9.0 |
| 5+ | 823.2178 | 823.2168 | -0.0010 | 54.5 |
| 4+ | 1028.7704 | 1028.7692 | -0.0012 | 100.0 |
| 3+ | 1371.3581 | 1371.3564 | -0.0017 | 53.2 |
| 2+ | 2056.5335 | 2056.5310 | -0.0025 | 9.0 |
Gravimetric mass balance
Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.
| Component | Determination | %w/w of cake |
|---|---|---|
| Water | Karl Fischer | 4.63 |
| Counter-ion (TFA) | ion chromatography | 6.19 |
| Residual solvent + inorganic residue | estimated | 0.88 |
| Total peptide content | by difference | 88.30 |
| Total | 100.00 CLOSES | |
Supplier certificate, as declared
The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.
| Figure | Supplier COA | This report | Index note |
|---|---|---|---|
| Purity (% area) | 99.38 | 99.00 | divergence +0.77 pp vs batch median |
| Total impurities (% area) | 0.62 | 1.00 | |
| Largest single impurity (% area) | 0.27 | 0.41 | |
| Water (%) | not stated | 4.63 | |
| Counter-ion (%) | not stated | 6.19 | |
| Peptide content (%w/w) | 91.7 | 88.30 | |
| Endotoxin (EU/mg) | not stated | not determined | |
| Method stated on certificate | YES | — | column, gradient and wavelength given |
Provenance and caveats
Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.
- Sample provenance
- Supplier-supplied
- Evidentiary weight
- Weaker evidence. Read with the caveat below.
- Chain of custody
- Supplier despatch → laboratory direct (courier, cold pack, 3 d) → assay. Submitter did not handle the vial.
- Assay date
- 04 Dec 2025
- Submitted to the index
- 10 Dec 2025
- Laboratory
- Janoshik Analytical, Ostrava, Czechia
- Method basis
- 30 min gradient · high-resolution MS
- Verification status
- VERIFIED
Annotations
No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.
Related records
Same batch — lot MKM-2507-D3230 n=9
| Report | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|
| AX-2025-020307 | MKM-2507-D3230 | PeptideMeter | 2025-Q4 | 98.93 | 5.02 | 107.0 | Supplier-supplied | 1 | MARGINAL |
| AX-2025-020308 | MKM-2507-D3230 | PeptideMeter | 2025-Q4 | 98.22 | 4.55 | — | Laboratory-retained | 1 | MARGINAL |
| AX-2025-020309 | MKM-2507-D3230 | Janoshik | 2025-Q4 | 98.19 | 4.85 | 97.1 | Buyer-sourced | 1 | MARGINAL |
| AX-2025-020310 | MKM-2507-D3230 | Kestrel | 2025-Q4 | 98.97 | 5.35 | 100.0 | Supplier-supplied | 1 | MARGINAL |
| AX-2025-020311 | MKM-2507-D3230 | VendorInvestigate | 2025-Q4 | 98.16 | 4.77 | 96.8 | Buyer-sourced | 1 | MARGINAL |
| AX-2025-020312 | MKM-2507-D3230 | Janoshik | 2025-Q4 | 98.91 | 4.96 | 106.1 | Supplier-supplied | 1 | MARGINAL |
| AX-2025-020313 | MKM-2507-D3230 | Janoshik | 2025-Q4 | 98.61 | 4.45 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2025-020315 | MKM-2507-D3230 | Janoshik | 2025-Q4 | 98.36 | 4.64 | 97.5 | Supplier-supplied | 1 | MARGINAL |
Cross-sections
| Report | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-041334 | WWB | WWB-2606-N3192 | Janoshik | 2026-Q3 | 98.83 | 5.04 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041932 | TFC | TFC-2604-X4301 | Janoshik | 2026-Q3 | 98.88 | 4.31 | — | Supplier-supplied | 0 | PASS |
| AX-2026-042347 | HJ | HJ-2608-C3931 | VendorInvestigate | 2026-Q3 | 98.80 | 3.41 | 100.2 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-041886 | JEEP | JEEP-2607-X3911 | Nordanalyt | 2026-Q3 | 99.19 | 4.03 | 96.4 | Supplier-supplied | 2 | MARGINAL |
| AX-2026-041337 | WWB | WWB-2606-N3192 | Nordanalyt | 2026-Q3 | 98.96 | 4.81 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042172 | Homopeptide | HOMO-2604-X8921 | Janoshik | 2026-Q3 | 99.64 | 5.16 | 91.9 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041767 | FGP | FGP-2602-M1508 | PeptideMeter | 2026-Q3 | 98.65 | 2.54 | — | Supplier-supplied | 2 | FAIL |
| AX-2026-041882 | JEEP | JEEP-2607-X3911 | Nordanalyt | 2026-Q3 | 99.17 | 4.52 | — | Supplier-supplied | 1 | MARGINAL |
| Report | Compound | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042943 | Adipotide | MKM-2606-K4013 | Janoshik | 2026-Q3 | 97.92 | 6.31 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042891 | CJC-1295 (no DAC) | MKM-2603-V2347 | Janoshik | 2026-Q3 | 99.28 | 3.63 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042942 | Adipotide | MKM-2606-K4013 | VendorInvestigate | 2026-Q3 | 97.04 | 5.56 | 94.6 | Buyer-sourced | 1 | FAIL |
| AX-2026-042914 | Gonadorelin | MKM-2604-A2596 | Janoshik | 2026-Q2 | 99.93 | 5.19 | — | Supplier-supplied | 0 | PASS |
| AX-2026-042884 | BPC-157 | MKM-2605-X2575 | Nordanalyt | 2026-Q2 | 98.12 | 2.89 | — | Laboratory-retained | 1 | MARGINAL |
| AX-2026-042946 | Tirzepatide | MKM-2601-L3752 | Medutest | 2026-Q2 | 97.71 | 8.10 | — | Supplier-supplied | 1 | FAIL |
| AX-2026-042911 | Gonadorelin | MKM-2604-A2596 | Medutest | 2026-Q2 | 99.08 | 5.55 | — | Buyer-sourced | 1 | MARGINAL |
| AX-2026-042932 | L-Glutathione (reduced) | MKM-2511-F2902 | Janoshik | 2026-Q2 | 98.57 | 8.41 | 92.9 | Supplier-supplied | 1 | MARGINAL |